News coverage about Cascadian Therapeutics (NASDAQ:CASC) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm ranks the sentiment of press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cascadian Therapeutics earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 44.8657249877838 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Shares of Cascadian Therapeutics (CASC) traded up $0.15 during trading on Friday, reaching $4.07. 271,162 shares of the company’s stock were exchanged, compared to its average volume of 285,624. Cascadian Therapeutics has a 12-month low of $3.18 and a 12-month high of $4.97. The company has a market cap of $198.20, a P/E ratio of -3.01 and a beta of 2.30.
Cascadian Therapeutics (NASDAQ:CASC) last issued its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.01. During the same quarter in the prior year, the company earned ($0.09) earnings per share. equities research analysts anticipate that Cascadian Therapeutics will post -1.27 earnings per share for the current year.
Separately, Zacks Investment Research raised shares of Cascadian Therapeutics from a “hold” rating to a “buy” rating and set a $4.50 price target for the company in a report on Monday, November 13th. Three investment analysts have rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. Cascadian Therapeutics has an average rating of “Hold” and an average target price of $5.63.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another site, it was copied illegally and reposted in violation of United States and international trademark and copyright laws. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/01/13/cascadian-therapeutics-casc-getting-somewhat-favorable-media-coverage-report-shows.html.
About Cascadian Therapeutics
Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.
Receive News & Ratings for Cascadian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.